SEATTLE--(BUSINESS WIRE)--Seattle-based Hagens Berman Sobol Shapiro LLP today filed a class-action lawsuit in the United States District Court for the Western District of Washington on behalf of shareholders of Dendreon Corp. (Nasdaq: DNDN) after the company’s stock plunged by more than $22 per share when the company withdrew its earnings guidance for the entire fiscal year based on failure to market and sell its prostate cancer therapy Provenge. After the news was released August 3, 2011, the Seattle-based company’s stock dropped by over 60 percent, reducing the company’s market value by over $3 billion.
